Literature DB >> 25017784

Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR‑126 in esophageal squamous cell carcinoma.

Haomiao Li1, Fanyu Meng1, Jun Ma2, Yongkui Yu1, Xionghuai Hua1, Jianjun Qin1, Yin Li1.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is a common histologic subtype in China. It has been suggested that abnormal expression of microRNAs (miRNAs) is associated with carcinogenesis. We investigated miR-126 expression and its potential targets in ESCC. The expression of miR-126 was detected in cancerous and paired paracancer tissues from 102 patients with ESCC. Target analysis of miR-126 was predicted using online tools. The effect of miR-126 expression on target proteins was assessed using miR-126 mimics or miR-126 inhibitors in ESCC cell lines. In addition, the impact of miR-126 on cell proliferation, apoptosis, migration and invasion was detected in ESCC cell lines. The expression of miR-126 was significantly lower in ESCC tissues, which was associated with tumor differentiation, lymph node metastasis, tumor in-depth and TNM stage. Insulin receptor substrate-1 (IRS-1) and Golgi phosphoprotein 3 (GOLPH3) were overexpressed in ESCC. Overexpression of IRS-1 was associated with cell differentiation, whereas GOLPH3 was related to lymph node metastasis, tumor invasion in-depth and TNM stage in ESCC patients. miR-126 mimics downregulated the expression of IRS-1 and GOLPH3 protein and suppressed the proliferation, migration and invasion of ESCC cells, whereas miR-126 inhibitors led to the opposite results. miR-126 suppressed the proliferation, migration and invasion of ESCC cells, and acted as a tumor suppressor in the carcinogenesis of ESCC. IRS-1 and GOLPH3 are downstream targets of miR-126 at the post-transcriptional level in ESCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25017784     DOI: 10.3892/or.2014.3327

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

Review 1.  The role of microRNA in esophageal squamous cell carcinoma.

Authors:  Kazuto Harada; Yoshifumi Baba; Takatsugu Ishimoto; Hironobu Shigaki; Keisuke Kosumi; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  J Gastroenterol       Date:  2016-01-21       Impact factor: 7.527

Review 2.  GOLPH3 links the Golgi, DNA damage, and cancer.

Authors:  Matthew D Buschman; Juliati Rahajeng; Seth J Field
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

3.  MicroRNA-126 accelerates IgE-mediated mast cell degranulation associated with the PI3K/Akt signaling pathway by promoting Ca2+ influx.

Authors:  Yuan Bao; Song Wang; Yang Gao; Wen Zhang; Haitao Jin; Yang Yang; Jiangyu Li
Journal:  Exp Ther Med       Date:  2018-07-23       Impact factor: 2.447

4.  Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A.

Authors:  Hongxia Chen; Lingmin Li; Shaojun Wang; Yupeng Lei; Qi Ge; Nonghua Lv; Xiaodong Zhou; Changyan Chen
Journal:  Oncotarget       Date:  2014-12-15

5.  MiR-126 Suppresses the Glucose-Stimulated Proliferation via IRS-2 in INS-1 β Cells.

Authors:  Hong Tao; Meng-meng Wang; Man Zhang; Shao-ping Zhang; Chun-hui Wang; Wen-jun Yuan; Tao Sun; Lan-jie He; Qi-kuan Hu
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

Review 6.  Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy.

Authors:  Marco Tomasetti; Wan Lee; Lory Santarelli; Jiri Neuzil
Journal:  Exp Mol Med       Date:  2017-01-20       Impact factor: 8.718

7.  PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.

Authors:  Junwei Zhu; Haomiao Li; Jun Ma; Haibo Huang; Jianjun Qin; Yin Li
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

8.  Prevention of neointimal formation using miRNA-126-containing nanoparticle-conjugated stents in a rabbit model.

Authors:  Masayasu Izuhara; Yasuhide Kuwabara; Naritatsu Saito; Erika Yamamoto; Daihiko Hakuno; Yasuhiro Nakashima; Takahiro Horie; Osamu Baba; Masataka Nishiga; Tetsushi Nakao; Tomohiro Nishino; Fumiko Nakazeki; Yuya Ide; Masahiro Kimura; Takeshi Kimura; Koh Ono
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

9.  miR-126 targeting GOLPH3 inhibits the epithelial-mesenchymal transition of gastric cancer BGC-823 cells and reduces cell invasion.

Authors:  Jiancai Ouyang; Fuhu Song; He Li; Rui Yang; Haicheng Huang
Journal:  Eur J Histochem       Date:  2020-10-28       Impact factor: 3.188

10.  Low levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma.

Authors:  Jun Kiuchi; Shuhei Komatsu; Taisuke Imamura; Keiji Nishibeppu; Katsutoshi Shoda; Tomohiro Arita; Toshiyuki Kosuga; Hirotaka Konishi; Atsushi Shiozaki; Kazuma Okamoto; Hitoshi Fujiwara; Daisuke Ichikawa; Eigo Otsuji
Journal:  Mol Cancer       Date:  2019-01-04       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.